Overweight Patients Achieve Ideal Body Weight Following Curative Gastrectomy Resulting in Better Long-term Prognosis
Overview
Affiliations
Background: The relationship between body mass index (BMI) and long-term outcome in gastric cancer patients following radical gastrectomy continues to be debated. We investigated the association between BMI, clinicopathological features, and prognosis in Chinese gastric carcinoma patients.
Methods: A retrospective consecutive cohort study was performed on 1,296 patients who underwent gastrectomy with curative intent at the Tianjin Cancer Institute Hospital between 1999 and 2004. The clinicopathological characteristics, overall 5-year survival rate (OS), and preoperative and six-month postoperative BMIs of both overweight (BMI ≥ 25 kg/m(2); H-BMI; n = 364) and non-overweight (BMI <25 kg/m(2); N-BMI; n = 932) patients were compared.
Results: Among these patients, 364 (28.1 %) were overweight. The OS was significantly higher in the H-BMI than N-BMI group (33.2 vs. 24.1 %, respectively; p < 0.001). Preoperative and six-month postoperative BMIs were 27.1 ± 2.0 and 24.8 ± 2.0 kg/m(2), respectively, in the H-BMI group (p < 0.001), whereas they were 21.7 ± 2.2 and 20.7 ± 2.2 kg/m(2), respectively, in the N-BMI group (p = 0.007). There was significantly better differentiation (p = 0.034), less distant metastases (p = 0.006), and a lower metastatic lymph node ratio (p = 0.014) observed in the H-BMI groups. Multivariate analyses indicated age, BMI, pathological tumor depth, distant metastases, metastatic lymph node ratio, and tumor size as independent prognostic factors.
Conclusions: Our findings suggest that overweight patients were less likely to have tumors with aggressive features and can achieve ideal body weight following curative gastrectomy, possibly resulting in better long-term prognosis.
Li Z, Cui L, Sun J, Liu W PLoS One. 2025; 20(1):e0317985.
PMID: 39874306 PMC: 11774357. DOI: 10.1371/journal.pone.0317985.
Modifiable risk factors for weight loss after cancer treatment in Korean gastric cancer survivors.
Park J, Kim J, Shin D, Shin J, Cho B, Song Y J Cancer Surviv. 2024; .
PMID: 39083113 DOI: 10.1007/s11764-024-01642-y.
Xing J, Cai J, Wang X, Zhang N, An D, Li F Surg Endosc. 2024; 38(9):4976-4985.
PMID: 38981881 PMC: 11362494. DOI: 10.1007/s00464-024-10952-2.
Jo H, Kim N, Jang J, Choi Y, Park J, Park Y Gut Liver. 2022; 17(2):243-258.
PMID: 36317512 PMC: 10018295. DOI: 10.5009/gnl220104.
Zhao L, Huang H, Wang Y, Wang T, Zhou H, Ma F World J Gastroenterol. 2020; 26(14):1613-1627.
PMID: 32327910 PMC: 7167420. DOI: 10.3748/wjg.v26.i14.1613.